glp-1 research Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Penn researchers say inconsistent GLP1

Additionally, pharmacovigilance analyses using the FDA Adverse Event Reporting System (FAERS) noted an increased number of thyroid-related reports, including hyperplasia and neoplasms, associated with GLP-1 receptor agonists

Mahapatro A, Bozorgi A, Obulareddy SUJ, Jain SM, Reddy Korsapati R, Kumar A, Patel K, Soltani Moghadam S, Arya A, Jameel Alotaibi A, Keivanlou MH, Hassanipour S, Hasanpour M, Amini-Salehi E

However, compounded GLP-1 medications are not FDA-approved

Limitations include user dependence requiring training and experience, potential for false positives and negatives, and inability to completely eliminate aspiration risk [61]

BMJ Open (2013) 3(9):e003201.10.1136/bmjopen-2013-003201 61 KahlesFMeyerCMllmannJDieboldSFindeisenHMLebherzCet alGLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering

Especially for a country like India, often called the worlds pharmacy, with its well-developed generics industry supplying around 20% of global off-patent medicines